News Background

Oxford, UK – 06 July 2020. OGT, A Sysmex Group Company, has today announced that from 1st July 2020, CytoCell® customers in China and Spain will be able to benefit from the established, comprehensive sales and support services of Sysmex. This significant addition to direct sales of CytoCell fluorescence in situ hybridization (FISH) products demonstrates the extensive collaboration between OGT and Sysmex, as well as the continuing strategy to reinforce this—further expansions across the entire OGT portfolio are planned in the current financial year.

The expansion involves Sysmex Shanghai, Sysmex Hong Kong and Sysmex Espana. Customers in China will continue to be able to use the current CytoCell distributor, Youning Biotech, however, the addition of Sysmex Shanghai offers broader coverage of the market through a larger commercial organisation – providing OGT with improved access to the Chinese market via the existing Sysmex Shanghai sales team and its extensive network of distributors. Sysmex España will be the country’s sole distributor for CytoCell products.

OGT’s CytoCell brand offers the widest range of FISH probes on the market and is well known and respected for its high-quality, reliability and cost-effectiveness as well as its renowned customer support, service and expertise. When purchasing probes via Sysmex, users benefit from all this, as well as the vast reach and reputation that Sysmex has in their established markets.

Commenting on the announcement, Gareth Thomson, Executive VP sales at OGT said: “We’re very pleased to announce these new collaborations with Sysmex Group companies. It builds on a series of success stories in other territories where we work with Sysmex’s distribution network. It provides us with an excellent opportunity to grow significantly in these territories benefiting from the established relationships with major customers in the regions.”

OGT’s CEO, John Anson, added: “Today’s announcement also highlights the wider strengthening of our relationship with Sysmex that goes beyond sales and distribution. OGT became part of Sysmex Group three years ago and since then we’ve been seeing ever-closer collaboration in other parts of the company as well—for example in the development of new products for next generation sequencing.”

OGT is also working towards expanding direct sales in certain territories of its CytoSure® cytogenetics and rare disease, and SureSeq™ cancer NGS portfolios.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.


For more information on the Company, please visit our website at


CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.


About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.


For more information about Sysmex Corporation and its affiliate companies, please visit

Related content

  • Share

You might also be interested in

NGS Scientist Looking At Slide

OGT's NGS panels to be featured in user workshop at AMP 2020

09 Nov 2020

In the workshop users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations.

NGS Scientist And Interpret Software

OGT launches breakthrough NGS panel for constitutional cytogenetics

30 Jan 2020

Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.


OGT continues move into molecular diagnostics markets

18 Nov 2019

MDSAP certification of new Cambridge facility smooths path to future IVD approvals.

All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter